Zacks Investment Research Lowers XOMA Corporation (XOMA) to Sell
Zacks Investment Research cut shares of XOMA Corporation (NASDAQ:XOMA) from a hold rating to a sell rating in a report issued on Wednesday morning.
According to Zacks, “XOMA Corporation is a biopharmaceutical company engaged in the discovery, development, and manufacturing of therapeutic antibodies to treat autoimmune, infectious, inflammatory, and oncological diseases. The company’s flagship product is gevokizumab, a humanized antibody to interleukin-1ß with potential for the treatment of the inflammatory cause of multiple diseases. XOMA Corporation, formally known as XOMA Ltd., is headquartered in Berkeley, California. “
A number of other brokerages also recently commented on XOMA. HC Wainwright started coverage on XOMA Corporation in a research report on Monday, June 12th. They issued a buy rating and a $15.00 price objective for the company. ValuEngine upgraded XOMA Corporation from a strong sell rating to a sell rating in a research report on Wednesday, July 12th. Finally, Wedbush reiterated a hold rating on shares of XOMA Corporation in a research report on Monday, August 14th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $14.00.
Shares of XOMA Corporation (NASDAQ:XOMA) opened at 19.40 on Wednesday. XOMA Corporation has a one year low of $3.96 and a one year high of $20.40. The stock has a 50 day moving average price of $10.79 and a 200-day moving average price of $7.61. The company’s market capitalization is $147.40 million.
A hedge fund recently raised its stake in XOMA Corporation stock. California Public Employees Retirement System grew its position in XOMA Corporation (NASDAQ:XOMA) by 95.5% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 21,780 shares of the biotechnology company’s stock after acquiring an additional 10,640 shares during the quarter. California Public Employees Retirement System owned 0.29% of XOMA Corporation worth $123,000 as of its most recent SEC filing. Institutional investors and hedge funds own 32.92% of the company’s stock.
About XOMA Corporation
XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for XOMA Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOMA Corporation and related companies with MarketBeat.com's FREE daily email newsletter.